Chlamydia research

Evofem Biosciences Announces Publication in American Journal of Obstetrics and Gynecology of AMPREVENCE Study of EVO100 for Chlamydia and Gonorrhea Prevention

Retrieved on: 
Tuesday, March 16, 2021
Chlamydiae, Infectious causes of cancer, Sexually transmitted diseases and infections, Medical specialties, Bacterial diseases, Gonorrhea, Pathogenic bacteria, Clinical medicine, Chlamydia, Chlamydia research

Evofem's dedication to bringing EVO100 to market as quickly and safely as possible underscores our commitment to serving women."

Key Points: 
  • Evofem's dedication to bringing EVO100 to market as quickly and safely as possible underscores our commitment to serving women."
  • Building on the AMPREVENCE results, Evofem is currently enrolling EVOGUARD , its pivotal Phase 3 clinical trial of EVO100 for prevention of chlamydia and gonorrhea in women.
  • The in-press accepted manuscript, entitledEVO100 Prevents Chlamydia and Gonorrhea in Women at High-Risk for Infection, is available online at https://www.sciencedirect.com/science/article/abs/pii/S0002937821001563 .
  • AMPREVENCE was conducted over approximately 16 weeks in women age 18 to 45 years who were at risk of urogenital chlamydia and gonorrhea infection.

Chlamydia Infections Pipeline Review 2020: Therapeutics Development, Assessment and Drug Profiles - ResearchAndMarkets.com

Retrieved on: 
Monday, November 9, 2020
Health, General Health, Chlamydiae, Sexually transmitted diseases and infections, Infectious causes of cancer, Epidemiology, Chlamydia, Medical specialties, Infection, Clinical medicine, Infections with a predominantly sexual mode of transmission, Medicine, Chlamydia research

The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects.

Key Points: 
  • The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Chlamydia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide evaluates Chlamydia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • Formulate corrective measures for pipeline projects by understanding Chlamydia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Evofem Biosciences to Present Data at the 2020 STD Prevention Virtual Conference from Phase 2b Trial of EVO100 for Prevention of Chlamydia and Gonorrhea in Women

Retrieved on: 
Monday, September 14, 2020
Sexually transmitted diseases and infections, RTT, Chlamydiae, Infectious causes of cancer, Medical specialties, Health, Clinical medicine, Gonorrhea, Chlamydia, Preventive healthcare, Chlamydia research

AMPREVENCE evaluated the safety and efficacy of the Company's investigational product candidate EVO100 for the prevention of urogenital chlamydia and gonorrhea in women.

Key Points: 
  • AMPREVENCE evaluated the safety and efficacy of the Company's investigational product candidate EVO100 for the prevention of urogenital chlamydia and gonorrhea in women.
  • The Phase 2b study met its primary and secondary endpoints, with women receiving EVO100 experiencing a relative risk reduction for chlamydia and gonorrhea infection of 50% and 78%, respectively, compared to women receiving placebo.
  • Positive, statistically significant data from the AMPREVENCE study along with a recent data review from the FDA has positioned Evofem to begin a Phase 3 clinical trial of EVO100 for prevention of chlamydia and gonorrhea in women in the fourth quarter of 2020.
  • "EVO100 has the potential to impact the health of millions of women by reducing infection rates of chlamydia and gonorrhea," said Kelly Culwell, M.D., Evofem Biosciences' Chief Medical Officer.

Chlamydia and Gonorrhea Positivity Surges in Women Ages 18-30 Years, Finds Quest Diagnostics Health Trends Study

Retrieved on: 
Thursday, September 3, 2020
Medical specialties, Infectious causes of cancer, Sexually transmitted diseases and infections, Clinical medicine, RTT, Chlamydiae, Infectious diseases, Infections with a predominantly sexual mode of transmission, Gonorrhea, Neisseria gonorrhoeae, Chlamydia, Chlamydia research

The new Health Trends study from Quest Diagnostics is believed to be one of the largest to examine rates of clinical laboratory test results for Chlamydia trachomatis (chlamydia) and Neisseria gonorrhoeae (gonorrhea) on a national scale.

Key Points: 
  • The new Health Trends study from Quest Diagnostics is believed to be one of the largest to examine rates of clinical laboratory test results for Chlamydia trachomatis (chlamydia) and Neisseria gonorrhoeae (gonorrhea) on a national scale.
  • The study examined 17,794,680 co-testing laboratory results for both infections from females aged 1230 years tested at Quest Diagnostics during 20102017.
  • In addition to showing sharp increases in the positivity rates of chlamydia and gonorrhea, the study also found that the positivity rates of both infections shifted toward older ages over the eight-year study period.
  • Yet, according to the study, the positivity rate for chlamydia for 27-year-old women in 2017 (3.5%) was the same as the positivity rate for 24-year-old women in 2010.

Chlamydia Infections - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 9, 2019
Health, Pharmaceutical, Chlamydiae, Sexually transmitted diseases and infections, Chlamydia infections, Infectious causes of cancer, Medical specialties, RTT, Chlamydia, Medicine, Health, Chlamydia research

The "Chlamydia Infections - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chlamydia Infections - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Chlamydia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Formulate corrective measures for pipeline projects by understanding Chlamydia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

BlueWillow Biologics Awarded Grant for Chlamydia Vaccine Development

Retrieved on: 
Wednesday, September 26, 2018
Sexually transmitted diseases and infections, Health, Microbiology, Chlamydia infections, Chlamydiae, RTT, Medicine, Infectious causes of cancer, Vaccine, National Institutes of Health, Chlamydia research

ANN ARBOR, Mich., Sept. 26, 2018 /PRNewswire/ -- BlueWillow Biologics today announced the company has been awarded an NIH Small Business Innovation Research (SBIR) grant for the development of an intranasal NanoVax vaccine for the prevention of chlamydia.

Key Points: 
  • ANN ARBOR, Mich., Sept. 26, 2018 /PRNewswire/ -- BlueWillow Biologics today announced the company has been awarded an NIH Small Business Innovation Research (SBIR) grant for the development of an intranasal NanoVax vaccine for the prevention of chlamydia.
  • There are more than 131 million new chlamydia infections worldwide each year1 and no approved vaccine currently exists to prevent the infection.
  • An intranasal NanoVax vaccine incorporating the novel BD584 antigen could prevent chlamydia infections from occurring in the first place, reducing cases of PID," said Mahony, an investigator under the grant.
  • With this SBIR grant, we will continue our research with the goal of advancing this preventive solution toward clinical trials," said Dr. Ali Fattom, Senior Vice President of Vaccine Research and Development, BlueWillow.